4.8 Article

Cellhesion VP enhances the immunomodulating potential of human mesenchymal stem cell-derived extracellular vesicles

期刊

BIOMATERIALS
卷 271, 期 -, 页码 -

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2021.120742

关键词

Cellhesion VP; MSC; 3D culture; EV; Immunomodulator

资金

  1. Nissan Chemical Corporation Ltd. [1403-20190096]

向作者/读者索取更多资源

The study demonstrated that 3D culture using Cellhesion VP enhanced the expression of stemness genes, migration ability, and extracellular vesicle (EV) production in hMSCs, leading to increased cell proliferation. The EVs derived from Cellhesion VP-primed hMSCs showed potential as a new therapeutic approach for immune and metabolic diseases, exhibiting distinct therapeutic profiles compared to EVs from 2D culture.
Mesenchymal stem cell (MSC) transplantation is a promising therapy for regenerative medicine. However, MSCs grown under two-dimensional (2D) culture conditions differ significantly in cell shape from those in the body, with downregulated stemness genes and secretion of paracrine factors. Here, we evaluated the effect of 3D culture using Cellhesion VP, a water-insoluble material composed of chitin-based polysaccharide fibers, on the characteristics of human Wharton?s jelly-derived MSCs (hMSCs). Cellhesion VP significantly increased cell proliferation after retrieval. Transcriptome analyses suggested that genes involved in cell stemness, migration ability, and extracellular vesicle (EV) production were enhanced by 3D culture. Subsequent biochemical analyses showed that the expression levels of stemness genes including OCT4, NANOG, and SSEA4 were upregulated and migration capacity was elevated in 3D-cultured hMSCs. In addition, EV production was significantly elevated in 3D cells, which contained a distinct protein profile from 2D cells. Gene and drug connectivity analyses revealed that the 2D and 3D EVs had similar functions as immunomodulators; however, 3D EVs had completely distinct therapeutic profiles for various infectious and metabolic diseases based on activation of disease-associated signaling pathways. Therefore, EVs from Cellhesion VP-primed hMSCs offer a new treatment for immune and metabolic diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据